Genomic Health, Inc. Announces Results of Clinical Survey Showing Use of Oncotype DX(R) Changes Treatment Recommendations for Women With Lymph Node-Positive Breast Cancer, Leading to Overall Reduction in Chemotherapy

SAN ANTONIO, Dec. 11 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX - News) today announced results from a clinical survey evaluating the impact of the Oncotype DX® Recurrence Score® result on physicians' adjuvant treatment recommendations for patients with node-positive, hormone receptor-positive breast cancer. The findings, presented as a poster at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium (Abstract # 2031), demonstrated that physicians frequently changed treatment recommendations for breast cancer patients with 1-3 positive nodes after integrating Recurrence Score results.